Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SanBio Co ( (JP:4592) ) has provided an update.
SanBio Co., Ltd. has secured a committed credit line agreement with MUFG Bank, Ltd. to support the commercialization of its product, AKUUGO, which has received conditional approval. The financial arrangement is expected to have a minor impact on the company’s earnings for the fiscal year ending January 2026.
The most recent analyst rating on (JP:4592) stock is a Sell with a Yen840.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.
More about SanBio Co
SanBio Co., Ltd. operates in the biotechnology industry, focusing on developing regenerative cell therapies for neurological disorders. Their primary product, AKUUGO, is aimed at intracranial implantation, and the company is working towards its commercialization.
Average Trading Volume: 5,064,093
Technical Sentiment Signal: Buy
Current Market Cap: Yen149.9B
For a thorough assessment of 4592 stock, go to TipRanks’ Stock Analysis page.